{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
Pirroksan by All-Union Scientific-Research Chemical-Pharmaceutical Institute
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Proroxan is a non-selective а-adrenoblocker. Proroxan was found to prevent the development of hypertensive crises and improve cerebral bioelectrical parameters in most of hypertensive patients. Proroxan has been used as an antihypertensive and in the treatment
of Ménière’s disease, motion sickness, and allergic dermatitis.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Tramazoline is a sympathomimetic drug that is used in the form of tramazoline hydrochloride in nasal decongestant preparations. Tramazoline is an α-adrenergic receptor agonist that inhibits secretion of nasal mucus.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Lidamidine, also known as WHR-1142A and Lidaral, is an alpha2-adrenergic receptor agonist that inhibits intestinal secretion, reduces intestinal transit, and inhibits smooth muscle contraction. Lidamidine hydrochloride is used to treat diarrhoea and other gastrointestinal disorders. Lidamidine’s intestinal antisecretory effects are
mediated through the activation of peripheral alpha-2 adrenoceptors. Lidamidine crosses
the blood brain barrier poorly and is therefore devoid of the centrally mediated alpha-2
effects that have limited the use of other alpha-2 adrenoceptor agonists in the intestinal
tract.